Geroprotectors & Nutraceuticals

1. What Are Geroprotectors?

Geroprotectors are interventions—pharmaceutical or nutritional—that slow aging processes and extend healthspan by targeting one or more of the hallmarks of aging. Unlike disease-specific treatments, geroprotectors act on fundamental aging mechanisms: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication.

The distinction between pharmaceuticals and nutraceuticals is increasingly blurred: compounds like berberine demonstrate glucose-lowering effects comparable to metformin, while NAD+ precursors target the same sirtuin pathways as pharmaceutical sirtuin activators. What matters is mechanistic validation, bioavailability, and demonstrated efficacy in humans.

2. Resveratrol: The SIRT1 Controversy

Resveratrol (3,5,4'-trihydroxy-trans-stilbene) catapulted into public consciousness in 2006 when David Sinclair's lab published evidence that it activated SIRT1, a longevity-associated protein, and extended lifespan in yeast, worms, flies, and mice. The compound became synonymous with the "red wine hypothesis" and spawned a multi-billion dollar supplement industry.

The Mechanism Debate

The resveratrol story exemplifies how scientific understanding evolves through controversy. Initial studies suggested resveratrol directly activated SIRT1 deacetylase activity. However, in 2009, Das and colleagues demonstrated that resveratrol does not directly activate SIRT1 with native peptide substrates—the observed activation in earlier studies was an experimental artifact resulting from fluorescently labeled substrates.

The Bioavailability Problem

Resveratrol's bioavailability is disastrously low—approximately 20% oral bioavailability with rapid metabolism and clearance. After oral administration, peak plasma concentrations are measured in nanomolar range, while in vitro effects require micromolar concentrations. Trans-resveratrol (the active isomer) undergoes extensive first-pass metabolism to sulfate and glucuronide conjugates with questionable biological activity.

Strategies to improve bioavailability include:

• Micronized formulations – reducing particle size for better absorption
• Liposomal delivery – encapsulation in lipid vesicles
• Co-administration with piperine – inhibiting glucuronidation (though this affects other medications)
• Methylated analogs – pterostilbene offers superior bioavailability (see section 13)

Clinical Evidence: Modest at Best

Meta-analyses of human trials show modest effects on metabolic parameters in specific populations (obese individuals, type 2 diabetics) but minimal effects in healthy adults. The disconnect between animal model efficacy and human outcomes likely reflects inadequate dosing due to bioavailability constraints and the substrate-selective nature of SIRT1 modulation.

Current consensus: resveratrol demonstrates proof-of-concept for sirtuin activation as a longevity pathway but requires formulation optimization or synthetic analogs (like pterostilbene) for clinically relevant effects.

3. Spermidine: Autophagy via EP300 Inhibition

Spermidine represents a more robust geroprotective mechanism than resveratrol, with clearer molecular pathways and more consistent human data. This naturally occurring polyamine declines with age, and supplementation demonstrates lifespan extension across multiple model organisms with emerging human validation.

The EP300-Autophagy Axis

Spermidine induces autophagy by inhibiting the acetyltransferase activity of EP300 (also known as p300), a histone acetyltransferase that acts as an endogenous repressor of autophagy. EP300 acetylates multiple autophagy-related proteins and transcription factors; spermidine-mediated EP300 inhibition reduces acetylation of cytoplasmic proteins including α-tubulin, promoting autophagic flux.

Dietary Sources and Supplementation

Spermidine is abundant in:

• Wheat germ (243 mg/kg) – highest concentration
• Natto (fermented soybeans, 200 mg/kg)
• Aged cheese (cheddar, 199 mg/kg)
• Mushrooms (89 mg/kg)
• Soy products (tofu, soy sauce)
• Legumes and whole grains

Typical Western diets provide 7-25 mg/day spermidine; Mediterranean and Asian diets with higher plant food content provide 15-35 mg/day. Supplement doses in clinical trials range from 1.2-6 mg/day, though optimal dosing remains under investigation.

Clinical Trials and Safety

The SmartAge Phase IIb trial is investigating 12 months of spermidine supplementation on memory performance in a double-blind, placebo-controlled design. Preliminary data suggests safety and tolerability, with ongoing assessment of cognitive and cardiovascular endpoints.

Spermidine's advantage over many geroprotectors: it's a naturally occurring metabolite with established safety profile, dietary sources for baseline intake, and multiple mechanisms (autophagy induction, anti-inflammatory effects, cardioprotection) targeting distinct aging hallmarks.

4. Urolithin A: Mitophagy Activation from Gut Microbiome

Urolithin A represents a fascinating intersection of microbiome metabolism, mitochondrial quality control, and precision nutrition. Unlike directly consumed geroprotectors, urolithin A is a gut microbiome-derived metabolite produced from ellagitannins found in pomegranates, berries, and nuts.

The Microbiome Dependency Problem

Only about 40% of the population possesses gut bacteria capable of converting ellagitannins to urolithin A, creating dramatic inter-individual variability in response to dietary ellagitannin consumption. Age, diet, and antibiotic exposure affect microbiome composition and urolithin A production capacity. This metabolic heterogeneity complicates dietary approaches but validates direct urolithin A supplementation.

Mitophagy Mechanism

Urolithin A induces mitophagy—selective autophagy of damaged mitochondria—through multiple pathways:

• PINK1/Parkin pathway activation – classical mitophagy signaling
• Mitochondrial fission promotion – separating damaged from healthy mitochondria
• Mitochondrial biogenesis stimulation – replacing cleared mitochondria with new, functional ones
• NAD+ pathway modulation – indirect effects on NAD+-dependent mitochondrial processes

The net effect: improved mitochondrial quality control, reduced oxidative damage, and enhanced cellular energy metabolism.

Amazentis/Mitopure Clinical Evidence

Mitopure (Amazentis SA) is a proprietary form of urolithin A with demonstrated bioavailability and safety. Pénélope Andreux and colleagues at Amazentis have published multiple clinical trials:

Practical Implementation

For the 60% of individuals who don't produce urolithin A efficiently, direct supplementation with Mitopure or similar bioavailable forms bypasses microbiome dependency. Dosing: 500-1,000 mg/day based on clinical trial evidence. Dietary ellagitannin sources (pomegranate, walnuts, berries) provide additional polyphenol benefits but unreliable urolithin A conversion.

5. Quercetin: Senolytic in Combination

Quercetin is a ubiquitous flavonoid found in apples, onions, berries, and tea. While it has modest standalone anti-inflammatory and antioxidant effects, quercetin's real significance emerged from its synergistic senolytic activity when combined with dasatinib, a tyrosine kinase inhibitor.

The Dasatinib + Quercetin (D+Q) Combination

Senolytic therapy targets senescent cells—cells that have permanently exited the cell cycle but resist apoptosis and secrete inflammatory factors (the senescence-associated secretory phenotype, or SASP). D+Q demonstrates complementary senolytic mechanisms:

• Dasatinib – targets senescent fat cell progenitors and endothelial cells by inhibiting ephrin receptors and Src family kinases involved in senescent cell anti-apoptotic pathways
• Quercetin – inhibits BCL-2 family anti-apoptotic proteins (BCL-xL, BCL-W) and PI3K/AKT survival signaling in senescent cells

The combination provides synergistic senolytic effects across different senescent cell types—neither compound alone achieves the broad senolytic activity of D+Q together.

Clinical Trial Evidence

Standalone Quercetin: Modest Benefits

Without dasatinib, quercetin acts as a general antioxidant and anti-inflammatory compound with unremarkable potency. Its bioavailability is poor (approximately 1-5% oral bioavailability) due to extensive first-pass metabolism. Quercetin phytosome formulations complexed with phosphatidylcholine improve absorption by 20-fold compared to standard quercetin.

6. Fisetin: Senolytic Potential

Fisetin (3,3',4',7-tetrahydroxyflavone) is a flavonoid found in strawberries, apples, persimmons, onions, and cucumbers. Of the flavonoids screened for senolytic activity, fisetin emerged as the most potent, according to Mayo Clinic research led by Matthew Yousefzadeh and colleagues.

Yousefzadeh 2018: Defining Fisetin's Senotherapeutic Effects

The 2018 EBioMedicine paper from the Robbins/van Deursen labs at Mayo demonstrated that fisetin reduces senescence markers across multiple tissues in both progeroid and naturally aged mice. Key findings:

• Acute or intermittent treatment (not continuous dosing) reduced senescent cell burden
• Hit-and-run senolytic mechanism – transient exposure sufficient for effect
• Late-life intervention – treatment beginning at 20 months (old age for mice) still extended healthspan and reduced age-related pathology
• Tissue-specific effects – particularly effective in fat, kidney, and heart tissue

Mayo Clinic Clinical Trials

Multiple human trials are evaluating fisetin's senolytic potential:

• Frailty in older women (NCT03675724) – completed trial examining whether fisetin reduces inflammatory and senescence markers
• COVID-19 in skilled nursing facilities – NIH-funded multicenter trial testing whether fisetin reduces severity in elderly COVID patients by targeting immunosenescence
• Vascular function in older adults (NCT06133634) – ongoing trial examining arterial stiffness and endothelial function
• Healthy volunteers pilot (NCT06431932) – safety and pharmacokinetics study

Typical dosing: 20 mg/kg/day for 2 consecutive days (approximately 1,400 mg/day for a 70 kg person), mirroring the intermittent protocol used for D+Q.

The Strawberry Bioavailability Question

Strawberries contain approximately 160 μg fisetin per gram fresh weight—a single serving (150g) provides only 24 mg fisetin, far below senolytic doses. Additionally, fisetin bioavailability from food sources is poor. Supplementation with concentrated fisetin extracts (standardized to 95%+ purity) is necessary to achieve therapeutic doses.

7. Sulforaphane: Nrf2 Activation and Phase II Detoxification

Sulforaphane represents one of the most extensively studied phytochemicals, with over 3,000 publications documenting its cancer chemopreventive, neuroprotective, and anti-inflammatory effects. The compound exemplifies hormetic benefits—mild stress signals that upregulate cellular defense systems.

The Glucoraphanin-Myrosinase System

Sulforaphane is not directly present in plants but forms from the interaction of:

• Glucoraphanin – a glucosinolate precursor, stable and water-soluble
• Myrosinase – a β-thioglucoside glucohydrolase enzyme released when plant cells are damaged

When you chew cruciferous vegetables (broccoli, Brussels sprouts, cauliflower), myrosinase converts glucoraphanin to sulforaphane. Cooking inactivates myrosinase, dramatically reducing sulforaphane bioavailability from cooked vegetables—unless gut bacteria possessing myrosinase-like enzymes compensate (microbiome-dependent, like urolithin A).

Nrf2 Activation: Master Antioxidant Switch

Sulforaphane's primary mechanism: activation of Nrf2 (nuclear factor erythroid 2-related factor 2), a transcription factor that upregulates over 200 genes involved in antioxidant defense, detoxification, and cellular protection. Under basal conditions, Nrf2 is sequestered by KEAP1 (Kelch-like ECH-associated protein 1) in the cytoplasm and rapidly degraded. Sulforaphane modifies cysteine residues on KEAP1, disrupting KEAP1-Nrf2 binding and allowing Nrf2 nuclear translocation.

Activated Nrf2 upregulates:

• Phase II detoxification enzymes – glutathione S-transferases, NAD(P)H quinone oxidoreductase, UDP-glucuronosyltransferases
• Antioxidant enzymes – glutathione peroxidase, superoxide dismutase, catalase
• Glutathione synthesis enzymes – γ-glutamylcysteine synthetase, glutathione reductase
• Heme oxygenase-1 (HO-1) – anti-inflammatory, cytoprotective

Cancer Chemoprevention Evidence

Over 50 clinical trials have examined sulforaphane's effects in humans. Notable findings:

• H. pylori eradication – broccoli sprout consumption reduced H. pylori colonization (gastric cancer prevention)
• Detoxification of aflatoxin and benzene – broccoli sprout beverage increased urinary excretion of carcinogenic metabolites in Chinese populations with high exposure
• Prostate cancer biomarkers – sulforaphane-rich broccoli sprout extract reduced PSA velocity in men with recurrent prostate cancer

Beyond Cancer: Metabolic and Neurological Effects

Clinical signatures of efficacy beyond cancer include:

• Improved autism spectrum disorder (ASD) scores – behavioral improvements in young men with ASD (placebo-controlled trial)
• Reduced schizophrenia symptoms – cognitive function improvements
• Type 2 diabetes management – reduced fasting glucose and HbA1c in diabetic patients (via AMPK activation and improved insulin sensitivity)
• Asthma relief – reduced airway inflammation and improved lung function

Bioavailability Optimization

To maximize sulforaphane availability:

1. Eat raw or lightly steamed sprouts – preserves myrosinase
2. If cooking mature broccoli, add mustard powder – provides exogenous myrosinase
3. Supplement with stabilized glucoraphanin + myrosinase – some formulations separate the two, combining them upon consumption
4. Consider sulforaphane supplements – direct sulforaphane (not precursor) bypasses myrosinase requirement but has stability challenges

8. Curcumin: The Bioavailability Disaster

Curcumin (diferuloylmethane), the yellow pigment in turmeric, is one of the most studied natural compounds with over 15,000 publications documenting anti-inflammatory, antioxidant, and anticancer effects. It's also one of the most frustrating from a translational perspective due to catastrophically poor bioavailability.

Why Bioavailability Fails

Curcumin faces multiple absorption and metabolism barriers:

• Poor water solubility – limits dissolution in intestinal fluids
• Low intestinal permeability – limited transport across enterocyte membranes
• Rapid metabolism – extensive phase II conjugation (glucuronidation, sulfation) in liver and intestine
• Instability at alkaline pH – degrades in intestinal environment
• Rapid clearance – short half-life (~1-2 hours)

The result: oral curcumin achieves nanomolar or undetectable plasma concentrations, while in vitro effects require micromolar concentrations—a 1,000-fold disconnect between effective doses in cells and achievable levels in humans.

NF-κB Inhibition: The Primary Mechanism

Curcumin's anti-inflammatory effects center on inhibition of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), a transcription factor that drives inflammatory gene expression. Curcumin prevents NF-κB phosphorylation and nuclear translocation, reducing expression of inflammatory cytokines (IL-6, TNF-α, IL-1β), chemokines, adhesion molecules, and inflammatory enzymes (COX-2, iNOS).

Secondary mechanisms include:

• Antioxidant effects – direct radical scavenging and Nrf2 activation
• Modulation of multiple signaling pathways – PI3K/AKT, MAPK, JAK/STAT
• Epigenetic effects – histone acetyltransferase and DNA methyltransferase modulation

Solving Bioavailability: Formulation Strategies

Clinical Evidence: Condition-Specific Efficacy

When bioavailability is addressed, curcumin demonstrates clinical efficacy in:

• Osteoarthritis – pain and function improvements comparable to NSAIDs in some trials
• Metabolic syndrome – modest improvements in insulin sensitivity, lipid profiles, inflammatory markers
• Depression – preliminary evidence for antidepressant effects (small trials)
• Post-surgical inflammation – reduced pain and inflammatory markers

Bottom line: Don't waste money on standard curcumin powder. Invest in enhanced bioavailability formulations (liposomal, phytosome, BCM-95®) or curcumin-piperine combinations if not on other medications.

9. Alpha-Ketoglutarate (AKG): TCA Cycle Intermediate with Epigenetic Effects

Alpha-ketoglutarate is a key intermediate in the tricarboxylic acid (TCA) cycle, linking cellular energy metabolism to epigenetic regulation through its role as a cofactor for dioxygenase enzymes that modify DNA and histones. Supplementation with calcium alpha-ketoglutarate (Ca-AKG) has emerged as a geroprotective intervention with provocative human data.

Multi-Level Mechanisms

AKG influences aging through interconnected pathways:

• TCA cycle support – replenishing intermediates that decline with age, enhancing mitochondrial energy production
• Cofactor for dioxygenases – AKG-dependent enzymes include TET demethylases (DNA demethylation), Jumonji histone demethylases (histone modification), and prolyl hydroxylases (collagen synthesis, HIF regulation)
• AMPK activation – AKG activates AMPK, mimicking aspects of caloric restriction
• mTOR modulation – AKG can inhibit mTOR signaling under certain conditions
• Stem cell maintenance – AKG regulates stem cell self-renewal and differentiation via epigenetic mechanisms

The Rejuvant Study: 8-Year Biological Age Reduction

The ABLE Trial: Rigorous Validation Underway

The ABLE (Alpha-ketoglutarate supplementation and BiologicaL agE) trial represents the gold-standard assessment of Ca-AKG's geroprotective potential:

• Design: Double-blind, placebo-controlled, randomized trial
• Population: 120 adults aged 40-60 years with biological age > chronological age (measured by DNA methylation clocks)
• Intervention: 1g/day sustained-release Ca-AKG vs. placebo for 6 months, with 3-month follow-up
• Primary outcome: Change in DNA methylation age from baseline to end of intervention
• Secondary outcomes: Physical function, metabolic parameters, inflammatory markers, safety
• Location: Singapore

Results from ABLE will clarify whether the dramatic effects suggested by Rejuvant data represent genuine epigenetic age reversal or artifacts of study design.

Practical Considerations

Calcium AKG is generally recognized as safe; the calcium provides additional benefit for bone health. Dosing in trials: 1g/day sustained-release formulation. AKG can be synthesized endogenously, but production declines with age—supplementation aims to restore youthful levels.

10. Berberine: The "Natural Metformin"

Berberine is an isoquinoline alkaloid extracted from various plants (goldenseal, Oregon grape, barberry) with a long history in traditional Chinese and Ayurvedic medicine. Its designation as "natural metformin" reflects strikingly similar metabolic effects: glucose-lowering, insulin-sensitizing, and AMPK activation—achieved through overlapping but distinct mechanisms.

The AMPK-Centered Mechanistic Hub

Berberine activates AMPK through mitochondrial complex I inhibition, increasing the AMP/ATP ratio and triggering AMPK phosphorylation. This distinguishes it from metformin, which primarily inhibits hepatic gluconeogenesis through complex I inhibition but acts through different upstream routes. The net result: converging on the same metabolic master switch.

Glucose-Lowering Evidence

Meta-analyses of randomized controlled trials in type 2 diabetics show berberine reduces:

• Fasting glucose by 15-25 mg/dL
• HbA1c by 0.5-1.0%
• Triglycerides by 20-30%
• LDL cholesterol by modest amounts

Effects are comparable to metformin in some trials, though direct head-to-head comparisons remain limited. Berberine demonstrates efficacy in metformin-naive patients and may offer additive benefits when combined with metformin.

Gut Microbiome Effects

Emerging evidence suggests berberine's metabolic effects are partially mediated by gut microbiome modulation:

• Increased short-chain fatty acid (SCFA) production – particularly butyrate, supporting gut barrier integrity and metabolic signaling
• Altered bile acid metabolism – affecting FXR and TGR5 signaling
• Shifts in bacterial composition – increased beneficial bacteria (Akkermansia muciniphila, Lactobacillus) and decreased pathogenic species

Synergistic Combination: Metformin + Berberine

A 2025 study demonstrated that metformin and berberine synergistically ameliorate NAFLD (non-alcoholic fatty liver disease) by activating AMPK, downregulating SREBP1 and FASN (fatty acid synthesis enzymes), and improving lipid metabolism. The combination offers:

• Convergent AMPK activation through different upstream pathways
• Complementary effects on liver, muscle, and adipose tissue
• Enhanced gut microbiome modulation
• Potential for dose reduction of each compound while maintaining efficacy

Clinical Development: Berberine Ursodeoxycholate

HTD1801 (berberine ursodeoxycholate), an ionic-salt derivative with improved bioavailability, is in Phase III trials for NAFLD and type 2 diabetes. It's being directly compared with dapagliflozin (an SGLT2 inhibitor), exemplifying the therapeutic potential of optimized berberine formulations.

Dosing and Bioavailability

Standard berberine bioavailability is poor (<5%), necessitating higher oral doses. Typical dosing: 500 mg three times daily with meals (1,500 mg/day total). Taking with meals reduces gastrointestinal side effects (diarrhea, cramping) and may improve absorption. Next-generation formulations (liposomal, phytosome, salt derivatives like HTD1801) aim to improve bioavailability and reduce dosing frequency.

11. Astaxanthin: Mitochondrial Antioxidant Crossing the Blood-Brain Barrier

Astaxanthin is a fat-soluble carotenoid (keto-carotenoid) that gives salmon, shrimp, and flamingos their pink-red color. Among antioxidants, astaxanthin possesses unique properties: 10-100× more potent antioxidant activity than vitamin E or β-carotene, membrane-spanning orientation allowing simultaneous protection of lipid bilayer inner and outer surfaces, and ability to cross the blood-brain barrier.

Mitochondrial Targeting and Membrane Protection

Astaxanthin's molecular structure—long conjugated double-bond chain with polar end groups—allows it to span cellular and mitochondrial membranes, positioning hydroxyl groups at membrane surfaces while the polyene chain resides within the lipid bilayer. This unique orientation provides:

• Protection against lipid peroxidation – neutralizing radicals throughout membrane depth
• Mitochondrial membrane stabilization – preserving membrane potential and preventing cytochrome c release
• Reduction of mitochondrial ROS production – particularly hydrogen peroxide
• Restoration of mitochondrial function – astaxanthin pretreatment significantly inhibits H₂O₂-induced apoptosis of primary cortical neurons

Nrf2 Pathway Activation

Beyond direct radical scavenging, astaxanthin activates the Nrf2 pathway (like sulforaphane), upregulating endogenous antioxidant enzymes including:

• Superoxide dismutase (SOD)
• Catalase
• Glutathione peroxidase
• Heme oxygenase-1 (HO-1)

This dual mechanism—direct antioxidant activity plus upregulation of cellular defense systems—provides sustained protection beyond the compound's presence.

Blood-Brain Barrier Penetration

Astaxanthin's lipophilic nature and molecular structure enable it to cross the blood-brain barrier, accumulating in brain tissue where it:

• Protects neurons against oxidative damage
• Inhibits neuroinflammation and microglial activation
• Modulates neurotrophic factors (BDNF)
• Reduces amyloid-β accumulation (Alzheimer's models)
• Protects against dopaminergic neuron loss (Parkinson's models)

Recent formulation advances (nanoparticles, liposomes) further enhance brain delivery, increasing therapeutic potential for neurodegenerative diseases.

Anti-Inflammatory Mechanisms

Astaxanthin suppresses neuroinflammation through multiple pathways:

• NF-κB inhibition – reducing inflammatory cytokine expression (TNF-α, IL-6, IL-1β)
• Microglial M1→M2 polarization – shifting from pro-inflammatory to anti-inflammatory phenotype
• MAPK pathway modulation – reducing inflammatory signaling cascades
• Inflammasome inhibition – particularly NLRP3, implicated in neurodegenerative diseases

Clinical Applications

Human studies demonstrate benefits in:

• Exercise recovery – reduced muscle damage markers, decreased delayed-onset muscle soreness
• Cardiovascular health – improved lipid profiles, reduced oxidative stress in arterial walls
• Eye health – reduced eye fatigue, improved accommodation, protection against macular degeneration
• Skin protection – UV damage reduction, improved skin elasticity and moisture
• Cognitive function – preliminary evidence for improved processing speed and memory in older adults

Dosing and Sources

Natural sources: wild-caught salmon (5-40 mg/kg), krill, shrimp, and Haematococcus pluvialis microalgae (the primary commercial source). Typical supplement dosing: 4-12 mg/day, with higher doses (20+ mg/day) used in some clinical trials. Astaxanthin is fat-soluble; take with meals containing dietary fat for optimal absorption.

12. CoQ10/Ubiquinol: Electron Transport and Statin Depletion

Coenzyme Q10 (ubiquinone/ubiquinol) is an essential component of the mitochondrial electron transport chain (ETC) and a lipid-soluble antioxidant. While the body synthesizes CoQ10, production declines with age, and certain medications—particularly statins—deplete CoQ10 levels, creating clinical relevance for supplementation.

Dual Roles: Energy Production and Antioxidant Defense

1. Electron Transport Chain: CoQ10 shuttles electrons from Complex I (NADH dehydrogenase) and Complex II (succinate dehydrogenase) to Complex III (cytochrome bc1 complex), enabling ATP synthesis. Decreased CoQ10 levels limit ETC flux, reducing ATP production and impairing cellular energy metabolism.

2. Antioxidant Function: The reduced form (ubiquinol) directly scavenges lipid peroxyl radicals in mitochondrial and cellular membranes, regenerates vitamin E, and protects against oxidative damage to lipids, proteins, and DNA.

The Statin Problem

Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. Unfortunately, the same mevalonate pathway produces CoQ10, making statin-induced CoQ10 depletion an inevitable consequence of these widely prescribed drugs.

Ubiquinone vs. Ubiquinol

CoQ10 exists in two redox states:

• Ubiquinone – oxidized form, requires enzymatic reduction to ubiquinol for antioxidant activity
• Ubiquinol – reduced form, directly active as antioxidant

The body interconverts these forms, but aging and certain disease states impair this conversion. Ubiquinol supplementation bypasses the reduction requirement, potentially offering advantages in older adults or those with impaired redox capacity. Some evidence suggests ubiquinol achieves higher plasma levels than equivalent doses of ubiquinone, though clinical outcome differences remain unclear.

MitoQ: Mitochondria-Targeted CoQ10

Mitoquinone (MitoQ) is a synthetic derivative: CoQ10's antioxidant "head" attached to a lipophilic triphenylphosphonium (TPP+) cation that drives accumulation in mitochondria (several hundred-fold higher concentration than untargeted CoQ10). This mitochondrial targeting enhances antioxidant effects specifically where ROS production is highest.

Preclinical studies show MitoQ reduces mitochondrial oxidative damage more effectively than CoQ10. However, a 2025 study found: "MitoQ and CoQ10 supplementation mildly suppresses skeletal muscle mitochondrial hydrogen peroxide levels without impacting mitochondrial function in middle-aged men"—suggesting that H₂O₂ suppression may not translate to functional improvements in healthy individuals.

MitoQ remains under investigation for conditions with clear mitochondrial dysfunction: Parkinson's disease, chronic kidney disease, heart failure, and fatty liver disease.

Practical Recommendations

• For statin users: Consider 100-200 mg/day ubiquinol, especially if experiencing muscle symptoms
• For aging adults (>60 years): 100-200 mg/day ubiquinol or ubiquinone to compensate for age-related decline
• For heart failure patients: Higher doses (200-300 mg/day) based on clinical trial evidence (Q-SYMBIO trial)
• Take with fat-containing meals: CoQ10 is fat-soluble; absorption increases significantly with dietary fat

A 2025 study cautioned: "CoQ10 supplementation raises plasma levels without improving mitochondrial function in older adults"—highlighting the gap between biomarker changes and functional outcomes. CoQ10 may be most beneficial when clear deficiency or mitochondrial dysfunction exists, rather than as a universal supplement.

13. Pterostilbene: Methylated Resveratrol with Superior Bioavailability

Pterostilbene (3,5-dimethoxy-4'-hydroxy-trans-stilbene) is resveratrol's methylated cousin—structurally similar but with two methoxy groups replacing hydroxyl groups. This seemingly minor modification produces dramatic pharmacokinetic improvements while retaining (and in some cases enhancing) biological activity.

The Methylation Advantage

Methylation confers superior bioavailability through multiple mechanisms:

• Increased lipophilicity – better membrane permeability and cellular uptake
• Reduced first-pass metabolism – methoxy groups resist glucuronidation and sulfation
• Enhanced hepatic stability – slower enzymatic degradation
• Longer half-life – sustained plasma concentrations

The result: pterostilbene achieves ~80% oral bioavailability compared to resveratrol's ~20%—a four-fold improvement. Plasma levels of pterostilbene (parent compound + metabolites) significantly exceed those of resveratrol at equivalent doses.

SIRT1 Activation and Beyond

Pterostilbene activates SIRT1 through the same substrate-selective stabilization mechanism as resveratrol, but with enhanced potency in some assays. A 2021 study found: "Resveratrol and pterostilbene effectively inhibited mitochondrial ROS production and promoted mitochondrial biogenesis via SIRT1 signaling pathway"—with pterostilbene demonstrating superior efficacy in protecting against oxidative stress-induced mitochondrial dysfunction and intestinal injury.

Mechanisms include:

• SIRT1 activation – deacetylation of PGC-1α, FOXO transcription factors, p53
• Nrf2 upregulation – increased SOD and other antioxidant enzymes
• Mitochondrial biogenesis – increased mitochondrial mass and function
• Anti-inflammatory effects – NF-κB inhibition, reduced cytokine production
• Neuroprotection – SIRT1-dependent protection against amyloid-β toxicity in Alzheimer's models

Epigenetic Effects: SIRT1-Dependent DNA Damage Response

A 2015 study in triple-negative breast cancer found that combined resveratrol and pterostilbene treatment altered DNA damage response by affecting SIRT1 and DNMT (DNA methyltransferase) enzyme expression, including SIRT1-dependent regulation of γ-H2AX (DNA damage marker) and telomerase. This suggests epigenetic modulation beyond simple antioxidant effects.

Clinical Evidence

While pterostilbene has fewer human trials than resveratrol (being a more recent focus), existing studies show:

• Metabolic effects – improved lipid profiles (reduced LDL, increased HDL) in hypercholesterolemic adults
• Cognitive function – preliminary evidence for improved memory in older adults (small trial)
• Blood pressure – modest reductions in hypertensive individuals

The superior bioavailability suggests pterostilbene may achieve effects at lower doses than resveratrol, though head-to-head human trials are needed.

Practical Implementation

Typical dosing: 50-250 mg/day pterostilbene (compared to 150-500 mg resveratrol), reflecting the improved bioavailability. Pterostilbene is found in small amounts in blueberries and grapes but at concentrations too low for therapeutic effects—supplementation is necessary.

Given the bioavailability advantage and comparable (or superior) biological activity, pterostilbene represents a more rational choice than resveratrol for those seeking stilbene-based geroprotection.

14. Stacking Principles: Synergy, Redundancy, Timing, and Cycling

The promise of geroprotector combinations lies in targeting multiple aging hallmarks simultaneously. However, stacking introduces complexity: potential for synergistic benefits or antagonistic interactions, increased side effect risk, and the practical challenge of optimizing timing and cycling. Evidence-based stacking requires mechanistic understanding, not shotgun polypharmacy.

Synergy vs. Redundancy

The Exercise Interaction Problem

A critical 2023 review in BMC Biology highlighted a troubling finding: frequent (daily) dosing of leading geroprotectors blunts exercise-induced improvements in cardiorespiratory fitness, muscle size/strength/power, and insulin sensitivity. The mechanism: many geroprotectors mimic aspects of exercise (AMPK activation, mitochondrial biogenesis, oxidative stress adaptation). Continuous geroprotector exposure may create a "ceiling effect," preventing the additional adaptive response to exercise.

Timing Strategies

Morning dosing: Compounds affecting metabolism and energy (berberine, CoQ10, AKG) align with circadian rhythms when taken in morning.

Evening dosing: Spermidine may enhance autophagy during overnight fasting. Some users report sleep disruption with evening pterostilbene/resveratrol.

With meals vs. fasting: Fat-soluble compounds (astaxanthin, CoQ10, pterostilbene, curcumin) require dietary fat for absorption—take with meals. AMPK activators (berberine, AKG) may be more effective with meals to blunt postprandial glucose spikes.

Cycling Protocols

Emerging evidence suggests cycling prevents tolerance and preserves physiological responsiveness:

• Senolytics (D+Q, fisetin): 2-3 days monthly or quarterly—not continuous. "Hit-and-run" mechanism requires only transient exposure.
• AMPK activators (berberine, metformin): Consider 5 days on/2 days off, or 3 weeks on/1 week off to prevent metabolic adaptation
• Sirtuin activators: Intermittent dosing may mimic hormetic stress; continuous exposure may reduce adaptive response

A 2026 protocol guide suggested: "Low, cyclical dosing is sufficient—it's not about forcefully pushing the body into a state, but about reminding cells of their natural programming."

Evidence-Based Stack Examples

Metabolic optimization stack:

• Berberine 500mg 3×/day with meals (or metformin 500-1000mg 2×/day)
• AKG 1g/day sustained-release
• CoQ10/ubiquinol 100-200mg/day with fat-containing meal

Mitochondrial support stack:

• Urolithin A 500-1000mg/day
• CoQ10/ubiquinol 200mg/day
• Astaxanthin 8-12mg/day with meals
• NAD+ precursor (NMN 250-500mg or NR 300mg)

Senescent cell clearance protocol (quarterly):

• Days 1-2: Dasatinib 100mg + Quercetin 1250mg
• Days 3-4: Fisetin 20mg/kg
• Days 5-90: No senolytics
• Repeat every 3 months

15. Evidence Hierarchy: Proven, Promising, and Hype

Not all geroprotectors are created equal. A rational approach requires distinguishing robust evidence from preliminary findings and outright marketing hype. This hierarchy ranks compounds by strength of evidence from preclinical models through human outcomes.

What Constitutes "Proven"?

For a geroprotector to merit "strong evidence" designation:

1. Lifespan/healthspan extension in mammals (mice minimum, ideally non-human primates)
2. Mechanistic understanding linked to hallmarks of aging
3. Bioavailability and pharmacokinetics demonstrating achievable tissue concentrations
4. Randomized controlled trials in humans with clinically relevant endpoints (not just biomarkers)
5. Safety profile in long-term use

By this standard, no nutraceutical fully qualifies—even the best (urolithin A, D+Q) lack lifespan data in humans (which requires decades). What we can assess: mechanism validity, biomarker improvements, and functional outcomes (muscle strength, cognitive performance, metabolic parameters) that correlate with healthspan.

Distinguishing Signal from Noise

Red flags suggesting hype over substance:

• Only in vitro data – cells in dishes differ vastly from whole organisms
• Single animal model – C. elegans lifespan extension doesn't predict mammalian effects
• Biomarker changes without functional outcomes – increased NAD+ levels mean nothing if performance/health unchanged
• Proprietary blends without disclosed doses – impossible to assess efficacy or compare to research
• Extreme health claims – "reverses aging," "extends lifespan 20 years" without human outcome data

Green flags indicating legitimate potential:

• Multiple independent research groups replicating findings
• Publication in peer-reviewed journals (not just company websites)
• Registered clinical trials on ClinicalTrials.gov with results posted
• Mechanistic coherence with known aging biology
• Dose-response relationships demonstrating biological activity
• Safety data from long-term use (years, not weeks)

Conclusion: Building an Evidence-Based Geroprotector Strategy

The geroprotector landscape spans from well-validated interventions approaching pharmaceutical rigor (urolithin A, D+Q) to compounds with sound mechanisms but bioavailability challenges (resveratrol, curcumin) to promising early-stage candidates awaiting human validation (spermidine, AKG, pterostilbene). Rational implementation requires:

Foundational Principles

1. Mechanism over marketing: Understand how a compound targets aging hallmarks, not just manufacturer claims.
2. Bioavailability matters: The most potent in vitro compound is useless if it doesn't reach tissues at effective concentrations. Prioritize formulations with demonstrated pharmacokinetics.
3. Human data > animal models: Mouse lifespan extension generates hypotheses; human RCTs with functional outcomes provide answers.
4. Synergy through mechanistic diversity: Stack compounds targeting different pathways (autophagy + senescence clearance + NAD+ restoration), not multiple weak activators of the same pathway.
5. Respect exercise adaptations: Intermittent dosing and exercise-free windows prevent geroprotectors from blunting beneficial training responses.
6. Individual variability: Gut microbiome composition (urolithin A conversion), genetic polymorphisms (NAD+ synthesis enzymes), baseline health status, and concurrent medications all affect response.
7. Monitor outcomes: Track blood biomarkers (metabolic panel, inflammatory markers, possibly epigenetic clocks) and functional measures (strength, endurance, cognitive performance) rather than assuming supplements work.

Highest-Priority Interventions

If building a minimal effective stack based on current evidence:

• Urolithin A (500-1000mg/day) – strongest human mitophagy data
• Berberine (1500mg/day) or metformin (if prescribed) – metabolic optimization, AMPK activation
• Sulforaphane (from broccoli sprouts or stabilized supplement) – Nrf2 activation, phase II detox, cancer prevention
• Quarterly senolytic protocol (D+Q or fisetin) – senescent cell clearance
• NAD+ precursor (NMN or NR, 250-500mg/day) – sirtuin pathway support (see NAD+ precursors)

This core addresses: mitochondrial quality control, metabolic regulation, oxidative defense, cellular senescence, and NAD+ decline—hitting 5+ hallmarks of aging with strong mechanistic rationale and emerging human validation.

The Bigger Picture

Nutraceutical geroprotectors represent accessible entry points into longevity interventions, but they're complements, not substitutes, for the foundational pillars: exercise, nutrition optimization, sleep, stress management, and social connection. The compounds covered here target molecular pathways affected by lifestyle, amplifying benefits when combined with health-promoting behaviors.

Pharmaceutical geroprotectors like rapamycin and metformin demonstrate more robust evidence in some domains, but accessibility barriers (prescription requirements, monitoring needs) make nutraceuticals valuable alternatives for motivated individuals willing to navigate the evidence themselves.

As the field matures, expect:

• Completion of ongoing trials (ABLE for AKG, SmartAge for spermidine, multiple D+Q and fisetin trials)
• Improved formulations addressing bioavailability challenges (liposomal, nanoparticle, prodrug strategies)
• Combination products with synergy validated in human trials
• Integration with epigenetic clocks and other aging biomarkers for personalized optimization
• Clearer dosing guidelines based on age, health status, and concurrent interventions

The geroprotector toolkit continues expanding. The key is implementing current knowledge while maintaining epistemic humility about what remains unknown, monitoring individual response, and adapting as evidence evolves.

Further Reading

Explore related topics in the research portal:

• Rapamycin and mTOR Inhibition
• Metformin as a Longevity Drug
• NAD+ Precursors: NMN, NR, and Niacin
• Senolytic Therapy and Cellular Senescence
• Autophagy and Cellular Renewal
• Sirtuin Biology and Longevity Pathways
• Mitochondrial Function and Aging
• The Hallmarks of Aging
• Key Researchers in Longevity Science
• Clinical Trials in Aging Research